The Northern California Cancer Program and its clinical research arm, the Northern California Oncology Group, through the continuation of the Cooperative Group Outreach program, plan to foster state-of-the-art cancer management for all patients treated in the communities by providing the opportunity for community health care teams to participate in cancer treatment protocols. Support to the new and established Outreach communities will be provided; at the same tiem, incentives will be available to enhance protocol accrual and participation. Developing communities will have access to heightened educational opportunities for physicians and a higher quality of care for patients. The Northern California Cancer Program will provide assistance to all communities in meeting responsibilities for the protection of human subjects. The coordinated network of community hospitals and physicians developed by this program will serve as a resource for the implementation of other appropriate cancer control research activities and for the National Cancer Institute evaluation programs related to the Cooperative Group Outreach Program. The Northern California Cancer program and the Northern California Oncology Group will continue to evaluate the extent to which this program performs its stated objectives by the analysis of such criteria as accrual, protocol compliance, data documentation through audits, and participation in all aspects of clinical research including protocol development and attendance at regularly scheduled Northern California Oncology Group meetings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA039098-02
Application #
3558298
Study Section
(SRC)
Project Start
1985-02-01
Project End
1987-07-31
Budget Start
1985-12-01
Budget End
1987-07-31
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Northern California Cancer Center
Department
Type
DUNS #
City
Fremont
State
CA
Country
United States
Zip Code
94538
Sneed, P K; Lamborn, K R; Larson, D A et al. (1996) Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 35:37-44
MacKenzie, M R; Wold, H; George, C et al. (1992) Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma. J Clin Oncol 10:1769-74
Carlson, R W; Doroshow, J H; Odujinrin, O O et al. (1990) Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group. Invest New Drugs 8:387-9
Carlson, R W; Borrison, R A; Sher, H B et al. (1990) A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy 10:211-6
Hohn, D C; Stagg, R J; Friedman, M A et al. (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7:1646-54
Carlson, R W; Billingham, M E; Kohler, M et al. (1987) Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study. Cancer Treat Rep 71:427-8
Valone, F H; Kohler, M; Fisher, K et al. (1987) A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuri NCI Monogr :175-7